Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of intravenous KK2269 alone and with docetaxel in adults with solid tumors
jRCT2031230419Phase 1Active, not recruiting
- Sponsor
- Kyowa Kirin
- Start
- Jan 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of KK2269 and docetaxel in Nonhematologic neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 2 more (2 arms), sponsored by Kyowa Kirin. Primary endpoints: Dose-limiting toxicities, Adverse events and 3 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
KK2269docetaxel
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031230419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230419.